RELATING TO HEALTH.

SB 967 requires Medicaid and private health insurance plans to cover intravenous ketamine therapy for treating depression. This directly affects people with depression who may seek this treatment but currently face coverage barriers. The bill appropriates state funds to support this coverage requirement, ensuring insurers must pay for the therapy. The legislation is currently in committee referral after passing its first reading.